CARDIOVASCULAR
hamburger

ABBOTT BOOTH HOURS

Wednesday, May 8 | 3:00 p.m. – 6:30 p.m.
Thursday, May 9 | 9:00 a.m. – 4:30 p.m.
Friday, May 10 | 9:00 a.m.– 4:30 p.m.

 

CASE PRESENTATIONS

Please join global thought-leaders presenting in the Abbott booth on cases using Abbott technology and products.

THURSDAY, MAY 9

9:40 a.m.

HD Mapping with Advisor HD Grid Mapping Catheter, SE in AF

Martin Lowe, MD (Barts Health London)

 

10:05 a.m.

Reducing Fluoroscopy in the EP Lab

Paul Zei, MD (Brigham & Women’s Hospital)

 

3:05 p.m.

Collaboration in HF Management

John Rickard, M.D., MPH (Cleveland Clinic Foundation)

 

3:30 p.m.

HD Mapping with Advisor HD Grid Mapping Catheter, SE in VT

Wendy Tzou, MD (University of Colorado)

 

4:00 p.m.

Optimizing Workflow in the EP Lab

Rodney Horton, MD (Texas Cardiac Arrhythmia)

FRIDAY, MAY 10

9:40 a.m.

SyncAV™ CRT in Device Optimization

Ulrika Birgersdotter-Green, MD (University of California San Diego Medical Center)

 

10:05 a.m.

Patient Connectivity

John IP, MD (Sparrow Hospital)

 

3:05 p.m.

HD Grid Mapping with Advisor HD Grid Mapping Catheter, SE in VT

Roderick Tung, MD (University of Chicago Hospital)

 

3:30 p.m.

HD Grid Mapping in AF Cases

Moussa Mansour, MD (Massachusetts General Hospital)

 

4:00 p.m.

Confirm Rx™ ICM

Harish Manyam, MD (Erlanger)

VIRTUAL REALITY POD

Visit Abbott at HRS for a unique engagement opportunity where you can walk into a virtual reality pod and experience a live case as if you were standing next to the physician performing the procedure. You’ll have an opportunity to choose from multiple cases showcasing Abbott EP Solutions including the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ with the EnSite™ Precision System and CRM technology with MultiPoint™ Pacing.


Time slots are available via sign up in the booth.

KEY CLINICAL SESSIONS

THURSDAY, MAY 9

8:00 a.m. - 9:30 a.m.

Oral Abstract Session: Arrhythmias Following CHD Surgery

Location: Room 203

S-AB16-03 (8:30 AM - 8:45 AM) – Validation and Utility of a Novel Mapping System in Ablation of Complex Arrhythmias in Adult Congenital Heart Disease: A Multi Centre UK Study

Vinit Sawhney, MD (London, United Kingdom)


12:15 p.m. - 1:15 p.m.

Moderated Poster Session: New Lessons in SVT

Location: EPicenter Lab 2

S-MP04-06 (1:05 PM - 1:15 PM) – Catheter Ablation of Atypical Atrial Flutter Using the HD-grid Mapping Catheter

Jippe C. Balt, MD, PhD (Nieuwegein, Netherlands)


3:35 p.m. - 4:15 p.m.

Moderated Poster Session: Defining Substrate Based Ventricular Arrhythmias - Novel Approaches to Mapping

Location: EPicenter Lab 3

S-MP08-03 (3:35 PM - 3:45 PM) – High Density Mapping of Dynamic Functional Late Potentials and Functional Late Repolarization Identifies Critical Sites for Ablation in Ventricular Tachycardia

Neil T. Srinivasan, CEPS-A, CCDS (London, United Kingdom)


2:00 p.m. - 4:30 p.m.

Poster Session III

Location: Hall ABC

S-PO03-163 – Point Density Exclusion (PDX) Electroanatomic Mapping of Endocavitary Structures

Jared D. Miller, MD (Portland, OR)

FRIDAY, MAY 10

9:30 a.m. - 12:00 p.m.

Poster Session IV

Location: Hall ABC

S-PO04-242 – Orientation Independent High Density Catheter Improves Substrate Mapping in Complex Congenital Heart Disease

Mary Niu, MD (Salt Lake City, UT)


2:00 p.m. - 4:30 p.m.

Poster Session V

Location: Hall ABC

S-PO05-124 – Comparison of Left Atrial Voltage Maps - Does Mapping Catheter Configuration Pattern Matter

Takanori Yamaguchi, MD (Saga, Japan)

FEATURED TECHNOLOGY

SPONSORED PROGRAMS AND EVENTS

WEDNESDAY, MAY 8

11:00 a.m.- 2:00 p.m.

AHP Hands-On Educational Session with Virtual EnSite Precision™ System Case Simulations

Location: Moscone Center Rooms 209/210-201/202


3:30 p.m. – 6:30 p.m.

AHP Training Village

Location: Outside the Exhibition Hall

Visit Abbott in our AHP Training Village to learn more about the Confirm Rx™ ICM with SharpSense™ Technology, programming SyncAV™ CRT technology and MultiPoint™ Pacing.


THURSDAY, MAY 9

9:00 a.m. – 12:30 p.m.

AHP Training Village

Location: Outside the Exhibition Hall

Visit Abbott in our AHP Training Village to learn more about the Confirm Rx™ ICM with SharpSense™ Technology, programming SyncAV™ CRT technology and MultiPoint™ Pacing.


6:00 p.m.- 7:30 p.m.

Women in EP Poster Session

Location: Waterbar

Contact us for additional information about this session.


6:00 p.m.- 10:00 p.m.

Canada/Latin America Event: A Comprehensive Review of Current Technologies and Treatment Modalities

Location: The Palace Hotel

Contact us for additional information about this session.

FRIDAY MAY 10

9:00 a.m.-12:30 p.m.

AHP Training Village

Location: Outside the Exhibition Hall

Visit Abbott in our AHP Training Village to learn more about the Confirm Rx™ ICM with SharpSense™ Technology, programming SyncAV™ CRT technology and MultiPoint™ Pacing.


6:00 p.m.- 9:00 p.m.

Asia Night

Location: The Fairmount

IMPORTANT SAFETY INFORMATION

INDICATIONS AND IMPORTANT SAFETY INFORMATION

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference Instructions for Use, inside the product carton (when available) or at manuals.sjm.com or eifu.abbottvascular.com for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Indications: The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart. Contraindications: The catheter is contraindicated for patients with prosthetic valves and patients with left atrial thrombus or myxoma, or interatrial baffle or patch via transseptal approach. This device should not be used with patients with active systemic infections. The catheter is contraindicated in patients who cannot be anticoagulated or infused with heparinized saline. Warnings: Cardiac catheterization procedures present the potential for significant x-ray exposure, which can result in acute radiation injury as well as increased risk for somatic and genetic effects, to both patients and laboratory staff due to the x-ray beam intensity and duration of the fluoroscopic imaging. Careful consideration must therefore be given for the use of this catheter in pregnant women.  Catheter entrapment within the heart or blood vessels is a possible complication of electrophysiology procedures. Vascular perforation or dissection is an inherent risk of any electrode placement. Careful catheter manipulation must be performed in order to avoid device component damage, thromboembolism, cerebrovascular accident, cardiac damage, perforation, pericardial effusion, or tamponade. Risks associated with electrical stimulation may include, but are not limited to, the induction of arrhythmias, such as atrial fibrillation (AF), ventricular tachycardia (VT) requiring cardioversion, and ventricular fibrillation (VF). Catheter materials are not compatible with magnetic resonance imaging (MRI). Precautions: Maintain an activated clotting time (ACT) of greater than 300 seconds at all times during use of the catheter. This includes when the catheter is used in the right side of the heart. To prevent entanglement with concomitantly used catheters, use care when using the catheter in the proximity of the other catheters. Maintain constant irrigation to prevent coagulation on the distal paddle. Inspect irrigation tubing for obstructions, such as kinks and air bubbles. If irrigation is interrupted, remove the catheter from the patient and inspect the catheter. Ensure that the irrigation ports are patent and flush the catheter prior to re-insertion. Always straighten the catheter before insertion or withdrawal. Do not use if the catheter appears damaged, kinked, or if there is difficulty in deflecting the distal section to achieve the desired curve. Do not use if the catheter does not hold its curve and/or if any of the irrigation ports are blocked. Catheter advancement must be performed under fluoroscopic guidance to minimize the risk of cardiac damage, perforation, or tamponade.

Indications: The TactiCath™ Quartz Contact Force Ablation Catheter and TactiCath™ Ablation Catheter, Sensor Enabled™ are indicated for use in cardiac electrophysiological mapping and for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used in conjunction with a compatible RF generator and three-dimensional mapping system. Contraindications: Do not use for any of the following conditions: certain recent heart surgery; prosthetic valves; active systemic infection; use in coronary vasculature; myxoma or intracardiac thrombus, or an interatrial baffle or patch; retrograde trans-aortic approach in patients with aortic valve replacement. Warnings: It is important to carefully titrate RF power; too high RF power during ablation may lead to perforation caused by steam pop. Contact force in excess of 70 g may not improve the characteristics of lesion formation and may increase the risk for perforation during manipulation of the catheter. Patients undergoing septal accessory pathway ablation are at risk for complete AV block which requires the implantation of a permanent pacemaker. Implantable pacemakers and implantable cardioverter/defibrillator may be adversely affected by RF current. Always verify the tubing and catheter have been properly cleared of air prior to inserting the catheter into the vasculature since entrapped air can cause potential injury or fatality. The temperature data transmitted by the sensor in this catheter is representative of the irrigated electrode only and does not provide tissue temperature data. Precautions: The long-term risks of protracted fluoroscopy and creation of RF induced lesions have not been established; careful consideration must be given for the use of the device in prepubescent children. When using the catheter with conventional EP lab system or with a 3-D navigational system, careful catheter manipulation must be performed, in order to avoid cardiac damage, perforation, or tamponade. Always maintain a constant saline irrigation flow to prevent coagulation within the lumen of the catheter. Care should be taken when ablating near structures such as the sino-atrial and AV nodes. Potential Adverse Events: Potential adverse events include, but are not limited to, cardiovascular related complications, including groin hematoma, pericardial effusion and infection. More serious complications are rare, which can include damage to the heart or blood vessels; blood clots (which may lead to stroke); tamponade; severe pulmonary vein stenosis; heart attack; esophageal fistula, or death.

Rx Only

Indications: The Confirm Rx™ ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation. The Confirm Rx™ ICM has not been specifically tested for pediatric use. Contraindications: There are no known contraindications for the insertion of the Confirm Rx™ ICM. However, the patient’s particular medical condition may dictate whether or not a subcutaneous, chronically inserted device can be tolerated. Adverse Events: Possible adverse events (in alphabetical order) associated with the device, include the following: Allergic reaction, Bleeding, Chronic nerve damage, Erosion, Excessive fibrotic tissue growth, Extrusion, Formation of hematomas or cysts, Infection, Keloid formation and Migration. Refer to the User’s Manual for detailed indications, contraindications, warnings, precautions and potential adverse events. Additional information: Clinicians must log onto Merlin.net™ Patient Care Network to view transmissions from patients’ Confirm Rx™ ICM. On Merlin.net™ PCN they can configure transmission schedules and enable or disable features on a patient’s myMerlin™ for Confirm Rx™ ICM mobile app. Review of transmissions is dependent on the clinician and may not happen immediately following delivery of such transmissions. Limitations: Patients may use their own Apple‡ or Android‡ mobile device to transmit information from their Confirm Rx™ ICM using the myMerlin™ for Confirm Rx™ mobile app. To do so the device must be powered on, app must be installed, Bluetooth® wireless technology enabled and data coverage (cellular or WiFi‡) available. The myMerlin™ for Confirm Rx™ mobile app provides periodic patient monitoring based on clinician configured settings. Data is resent if the transmission was not sent successfully. However, there are many internal and external factors that can hinder, delay, or prevent acquisition and delivery of ICM and patient information as intended by the clinician. These factors include: patient environment, data services, mobile device operating system and settings, ICM memory capacity, clinic environment, schedule/configuration changes, or data processing. An Abbott mobile transmitter is available for patients without their own compatible mobile device.

Rx Only

Brief Summary: Please review the Instructions for Use prior to using these devices for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Quartet™ LV lead

Indications and Usage: The Quartet lead has application as part of an Abbott Biventricular system.

Contraindications: The use of the Quartet lead is contraindicated in patients who:

  • Are expected to be hypersensitive to a single dose of 1.0 mg of dexamethasone sodium phosphate
  • Are unable to undergo an emergency thoracotomy procedure
  • Have coronary venous vasculature that is inadequate for lead placement, as indicated by venogram

MultiPoint™ Pacing and SyncAV™ CRT Technology

Indications: Abbott ICDs and CRT-Ds are intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias. AF Suppression™ pacing is indicated for suppression of paroxysmal or persistent atrial fibrillation in patients with the above ICD indication and sinus node dysfunction. In patients indicated for an ICD, CRT-Ds are also intended: to provide a reduction of the symptoms of moderate to severe heart failure (NYHA Functional Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy (as defined in the clinical trials section included in the Merlin™ PCS on-screen help) and have a left ventricular ejection fraction less than or equal to 35% and a prolonged QRS duration; to maintain synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic (permanent) atrial fibrillation and have NYHA Class II or III heart failure. Contraindications: Contraindications for use of the pulse generator system include ventricular tachyarrhythmias resulting from transient or correctable factors such as drug toxicity, electrolyte imbalance or acute myocardial infarction. Adverse Events: Include but are not limited to the following: acceleration of arrhythmias (caused by device), air embolism, allergic reaction, bleeding, cardiac tamponade, chronic nerve damage, death, erosion, exacerbation of heart failure, excessive fibrotic tissue growth, extracardiac stimulation (phrenic nerve, diaphragm, chest wall), extrusion, fluid accumulation, formation of hematomas or cysts, inappropriate shocks, infection, keloid formation, lead abrasion and discontinuity, lead migration/dislodgment, myocardial damage, pneumothorax, shunting current or insulating myocardium during defibrillation with internal or external paddles, potential mortality due to inability to defibrillate or pace, thromboemboli, venous occlusion, venous or cardiac perforation. Patients susceptible to frequent shocks despite antiarrhythmic medical management may develop psychological intolerance to an ICD or CRT-D system that may include the following: dependency, depression, fear of premature battery depletion, fear of shocking while conscious, fear of losing shock capability, imagined shocking (phantom shock). Refer to the User’s Manual for detailed indications, contraindications, warnings, precautions and potential adverse events.

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.  Indications and Usage: The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have had at least one heart failure hospitalization in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations. Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant. Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: Infection, Arrhythmias, Bleeding, Hematoma, Thrombus, Myocardial infarction, Transient ischemic attack, Stroke, Death, and Device embolization.

Rx Only

Important Safety Information

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. HeartMate 3™ LVAS Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short-and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in patients with advanced refractory left ventricular heart failure. HeartMate 3™ LVAS Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy. HeartMate 3™ LVAS Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or pump thrombosis.

TITLE

Abbott Cardiovascular at HRS 2019

LOCATION

San Francisco

DATE/TIME

05-08-2019 - 05-11-2019  9:00 AM-6:30 PM  | PST

ADDITIONAL INFORMATION

SJM-CV WEB-0519-0184

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?